Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Advanced Ovarian-, Fallopian Tube- and Primary Peritoneal Cancer

NCT04611126 is registered in ClinicalTrials.gov with Inge Marie Svane as lead sponsor.

NCT NCT04611126
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04611126 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Advanced Ovarian-, Fallopian Tube- and Primary Peritoneal Cancer
Lead sponsor
Inge Marie Svane
Phase
Phase 1/2
Overall status
Terminated
Start date
April 22, 2021
Completion date
March 3, 2024
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic fallopian tube cancer, metastatic ovarian cancer, peritoneal cancer